Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $16.24 in the prior trading day, Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed at $15.91, down -2.03%. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 1.06 million shares were traded. ADPT stock price reached its highest trading level at $16.47 during the session, while it also had its lowest trading level at $15.74.
Ratios:
Our goal is to gain a better understanding of ADPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.26 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 0.99.
On September 30, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.
On June 18, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $15.Craig Hallum initiated its Buy rating on June 18, 2025, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when LO FRANCIS sold 4,394 shares for $17.50 per share. The transaction valued at 76,895 led to the insider holds 315,978 shares of the business.
LO FRANCIS sold 113,890 shares of ADPT for $1,773,267 on Dec 15 ’25. The Chief People Officer now owns 315,978 shares after completing the transaction at $15.57 per share. On Dec 15 ’25, another insider, FRANCIS LO, who serves as the Officer of the company, bought 136,706 shares for $15.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 2428903168 and an Enterprise Value of 2429593088. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.61 while its Price-to-Book (P/B) ratio in mrq is 11.87. Its current Enterprise Value per Revenue stands at 9.612 whereas that against EBITDA is -40.425.
Stock Price History:
The Beta on a monthly basis for ADPT is 2.18, which has changed by 1.2567375 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, ADPT has reached a high of $20.76, while it has fallen to a 52-week low of $5.96. The 50-Day Moving Average of the stock is -3.59%, while the 200-Day Moving Average is calculated to be 28.53%.
Shares Statistics:
The stock has traded on average 2.26M shares per day over the past 3-months and 1838780 shares per day over the last 10 days, according to various share statistics. A total of 152.58M shares are outstanding, with a floating share count of 146.78M. Insiders hold about 3.86% of the company’s shares, while institutions hold 94.06% stake in the company. Shares short for ADPT as of 1765756800 were 9742510 with a Short Ratio of 4.31, compared to 1763078400 on 10368382. Therefore, it implies a Short% of Shares Outstanding of 9742510 and a Short% of Float of 8.17.
Earnings Estimates
The stock of Adaptive Biotechnologies Corp (ADPT) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.46 and -$0.51 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.57, with 7.0 analysts recommending between -$0.51 and -$0.65.
Revenue Estimates
7 analysts predict $59.28M in revenue for. The current quarter. It ranges from a high estimate of $61.5M to a low estimate of $57.7M. As of. The current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $47.46MFor the next quarter, 7 analysts are estimating revenue of $59.3M. There is a high estimate of $63.1M for the next quarter, whereas the lowest estimate is $55.08M.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $266.8M, while the lowest revenue estimate was $263M, resulting in an average revenue estimate of $264.62M. In the same quarter a year ago, actual revenue was $178.96MBased on 8 analysts’ estimates, the company’s revenue will be $267.68M in the next fiscal year. The high estimate is $275.5M and the low estimate is $255.7M.
